

PC #3
JC06 Rec'd PCT/PTO 14 SEP 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the United States Patent Application of:

Applicant: MATO DE LA PAZ, et al.

Application No.: 10/540,212

Date Filed: June 15, 2005

Title: METHOD OF DIAGNOSING
NON-ALCOHOLIC
STEATOHEPATITIS (NASH)
USING MOLECULAR
MARKERS

) Docket No.: 4258-112

) Examiner: Not Yet Assigned

) Art Unit: 1614


) Conf. No.: 5253

) Customer No.:

23448

FIRST CLASS MAIL CERTIFICATE

I hereby certify that I am mailing the attached documents to the Commissioner for Patents on the date specified, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, and First Class Mailed under the provisions of 37 CFR 1.8.


Candace White

September 12, 2005
Date of Mailing

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO/SB/08A. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- ☐ c. Attached is our check no. _____ in the amount of \$_____ in payment of the fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. _____ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check no. _____ in the amount of \$_____ in payment of the petition fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. 08-3284 as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).

Respectfully submitted,



Steven J. Hultquist
Reg. No. 28,021
Attorney for Applicant

INTELLECTUAL PROPERTY/
TECHNOLOGY LAW
Telephone: (919) 419-9350
Fax: (919) 419-9354


Attorney Ref: 4258-112

**INFORMATION
DISCLOSURE STATEMENT
BY APPLICANT**

COMPLETE IF KNOWN

Application Number	10/540,212
Filing Date	June 15, 2005
First Named Inventor	MATO DE LA PAZ, et al.
Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	4258-112

Sheet 4 of 1



NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AA	LU, S.C., et al. "Methionine Adenosyltransferase 1A Knockout Mice are Predisposed to Liver Injury and Exhibit Increased Expression of Genes Involved in Proliferation". PNAS, May 8, 2001, Vol. 98, No. 10, pg. 5560-5565	
	AB	MATO, J.M., et al. "S-Adenosylmethionine: A Control Switch That Regulates Liver Function" FASEB Journal., Vol. 16, January 2002, pages 15-26	
	AC	ZATLOUKAL, K., et al. "Alcoholic and Nonalcoholic Steatohepatitis" REV. ESP. PATOL., Vol. 32, No. 3, 1999, pages 293-294	
	AD	SANTAMARIA, E., et al. "Functional Proteomics of Nonalcoholic Steatohepatitis: Mitochondrial Proteins as Targets of S-adenosylmethionine" PNAS, Vol. 100, No. 6, March 18, 2003, pages 3065-3070	

Examiner signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

² Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).